METHOD FOR PREDICTION OF PROGRESSIVE CLINICAL COURSE OF EARLY FORMS OF NON-ALCOHOLIC FATTY LIVER DISEASE Russian patent published in 2022 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hepatology. TNF-α, interleukin-6, cytokeratin-18, alkaline phosphatase, gamma-glutamyl transpeptidase, glucose and fasting insulin levels are determined in peripheral blood in vitro. Further, the following syndromes are assessed: systemic inflammation, hepatocyte apoptosis, intrahepatic cholestasis and insulin resistance. In the presence of any two or more of the evaluated syndromes, the risk of progression of early forms of non-alcoholic fatty liver disease (NAFLD) is predicted, in the presence of only one of the analyzed syndromes or in the absence of each of them, the absence of a risk of progression of non-alcoholic fatty liver disease is determined.

EFFECT: invention makes it possible to simplify and reduce economic costs for assessment of NAFLD course prognosis, to improve quality of diagnostics, reducing the number of personnel involved for examination, justifying the use of a more active approach in patients with early forms of NAFLD with a high risk of progression.

1 cl, 5 tbl